Latest & greatest articles for statin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on statin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on statin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for statin

181. Statins: Is It Really Time to Reassess Benefits and Risks?

Statins: Is It Really Time to Reassess Benefits and Risks? Statins: is it really time to reassess benefits and risks? - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 22533536 Format MeSH and Other Data E-mail (...) Subject Additional text E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2012 May 10;366(19):1752-5. doi: 10.1056/NEJMp1203020. Epub 2012 Apr 25. Statins: is it really time to reassess benefits and risks? 1 . 1 Harvard Medical School and the Section of Clinical, Behavioral, and Outcomes Research, Joslin Diabetes Center, Boston, USA. Comment in [N Engl J Med. 2012] PMID: 22533536 DOI

NEJM2012

182. Effect of statin therapy on contrast-induced nephropathy after coronary angiography: a meta-analysis

Effect of statin therapy on contrast-induced nephropathy after coronary angiography: a meta-analysis Effect of statin therapy on contrast-induced nephropathy after coronary angiography: a meta-analysis Effect of statin therapy on contrast-induced nephropathy after coronary angiography: a meta-analysis Pappy R, Stavrakis S, Hennebry TA, Abu-Fadel MS CRD summary The authors concluded that statin use may be associated with a significant reduction in contrast-induced nephropathy, but acknowledged (...) a need for further research to confirm the conclusion. Concerns about the quality of included studies and the synthesis of non-randomised studies suggest that the cautious interpretation of findings recommended by the authors is justified. Authors' objectives To conduct a meta-analysis evaluating the impact of statin use on the incidence of contrast-induced nephropathy (CIN) in patients undergoing coronary angiography. Searching MEDLINE, EMBASE and The Cochrane Library were searched from inception

DARE.2012

183. Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170 255 patients from 76 randomized trials

Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170 255 patients from 76 randomized trials Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170 255 patients from 76 randomized trials Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170 255 patients from 76 randomized trials Mills EJ, Wu P, Chong G, Ghement I, Singh S, Akl EA, Eyawo O, Guyatt G, Berwanger O (...) , Briel M CRD summary This review concluded that statin therapies offered clear benefits in reducing cardiovascular outcomes across broad populations. The review appeared generally well conducted. The authors conclusions appear likely to be reliable, although it should be borne in mind that subgroup analysis by population type was conducted only for the primary outcome of cardiovascular disease mortality. Authors' objectives To assess the effects of statin therapy on cardiovascular mortality and other

DARE.2012

184. Meta-analysis of the cardiovascular benefits of intensive lipid lowering with statins

Meta-analysis of the cardiovascular benefits of intensive lipid lowering with statins Meta-analysis of the cardiovascular benefits of intensive lipid lowering with statins Meta-analysis of the cardiovascular benefits of intensive lipid lowering with statins Chan DK, O'Rourke F, Shen Q, Mak JC, Hung WT CRD summary The authors stated that intensive lipid lowering therapy with statins significantly reduced risk of stroke, major coronary events and cardiovascular or coronary heart disease deaths (...) in individuals at high risk of cardiovascular events. The review was largely well conducted, but the unknown methodological quality of included trials limits conclusive evidence of the review's reliability. Authors' objectives To evaluate the effects of lipid lowering therapy using higher-dose statins. Searching PubMed, EMBASE and The Cochrane Library were searched from 1966 to 2009. Search terms were reported. Reference lists and related links of relevant papers were reviewed for further studies. Study

DARE.2012

185. Statins for the prevention of contrast-induced nephropathy: a systematic review and meta-analysis

Statins for the prevention of contrast-induced nephropathy: a systematic review and meta-analysis Statins for the prevention of contrast-induced nephropathy: a systematic review and meta-analysis Statins for the prevention of contrast-induced nephropathy: a systematic review and meta-analysis Zhang T, Shen LH, Hu LH, He B CRD summary The authors concluded that limitations of the evidence precluded definitive conclusions regarding the protective effects of statins for contrast-induced (...) nephropathy. The review had some procedural limitations, but the authors acknowledged certain limitations of the included studies, such as heterogeneity, short-term follow-up and small clinical trial sample sizes. Given these limitations, the authors’ conclusions seem appropriate. Authors' objectives To assess the effects of statins in the prevention of contrast-induced nephropathy (CIN). Searching MEDLINE (1966), EMBASE (1974), The Cochrane Library (2010), CNKI (1994) and Conference Proceedings Citation

DARE.2012

186. High-sensitivity C-reactive protein, statin therapy, and risks of atrial fibrillation: an exploratory analysis of the JUPITER trial

High-sensitivity C-reactive protein, statin therapy, and risks of atrial fibrillation: an exploratory analysis of the JUPITER trial 22187510 2012 02 15 2012 04 16 2016 10 19 1522-9645 33 4 2012 Feb European heart journal Eur. Heart J. High-sensitivity C-reactive protein, statin therapy, and risks of atrial fibrillation: an exploratory analysis of the JUPITER trial. 531-7 10.1093/eurheartj/ehr460 Increasing evidence supports a role for inflammation in promoting atrial fibrillation (AF) and (...) statins have anti-inflammatory effects that may be relevant for the prevention of AF. However, studies of statin therapy and incident AF have yielded mixed results and not focused on individuals with an underlying pro-inflammatory response. We studied whether high-sensitivity C-reactive protein is associated with incident AF and whether treatment with rosuvastatin is associated with a lower incidence of AF compared with placebo. We randomized men and women with LDL cholesterol <130 mg/dL and high

EvidenceUpdates2012 Full Text: Link to full Text with Trip Pro

187. Statins for age-related macular degeneration.

Statins for age-related macular degeneration. BACKGROUND: Age-related macular degeneration (AMD) is a progressive late onset disorder of the macula affecting central vision. Age-related macular degeneration is the leading cause of blindness in people over 65 years in industrialized countries (Congdon 2003). Recent epidemiologic, genetic and pathological evidence has shown AMD shares a number of risk factors with atherosclerosis, leading to the hypothesis that statins may exert protective (...) effects in AMD. OBJECTIVES: To examine the effectiveness of statins compared with other treatments, no treatment, or placebo in delaying the onset and/or progression of AMD. SEARCH METHODS: We searched CENTRAL (which contains the Cochrane Eyes and Vision Group Trials Register) (The Cochrane Library 2011, Issue 9), MEDLINE (January 1950 to September 2011), EMBASE (January 1980 to September 2011), Latin American and Caribbean Health Sciences Literature Database (LILACS) (January 1982 to September 2011

Cochrane2012

188. Cost-effectiveness of statin therapy for primary prevention in a low-cost statin era

Cost-effectiveness of statin therapy for primary prevention in a low-cost statin era Cost-effectiveness of statin therapy for primary prevention in a low-cost statin era Cost-effectiveness of statin therapy for primary prevention in a low-cost statin era Lazar LD, Pletcher MJ, Coxson PG, Bibbins-Domingo K, Goldman L Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods (...) , the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to assess the cost-effectiveness of expanded statin prescribing strategies, using low cost generic drugs, for different populations. The authors concluded that low cost statins were cost-effective for people with only modestly elevated cholesterol or any coronary heart disease risk factor. The methods were not reported in full, particularly

NHS Economic Evaluation Database.2012

190. Statins and prevention of infections: systematic review and meta-analysis of data from large randomised placebo controlled trials

Statins and prevention of infections: systematic review and meta-analysis of data from large randomised placebo controlled trials Statins and prevention of infections: systematic review and meta-analysis of data from large randomised placebo controlled trials Statins and prevention of infections: systematic review and meta-analysis of data from large randomised placebo controlled trials van den Hoek HL, Bos WJ, de Boer A, van de Garde EM CRD summary The review findings did not support (...) the hypothesis that statins reduced the risk of infections. Despite some review limitations, the authors' conclusions appear appropriate and are likely to be reliable. Authors' objectives To evaluate whether the potential of statins to lower the risk of infections as published in observational studies is causal. Searching PubMed, EMBASE and Cochrane Central Register of Controlled Trials (CENTRAL) were searched to March 2011 for studies published in English; search terms were reported. Reference lists were

DARE.2012

191. Efficacy of statins for primary prevention in people at low cardiovascular risk: a meta-analysis

Efficacy of statins for primary prevention in people at low cardiovascular risk: a meta-analysis Efficacy of statins for primary prevention in people at low cardiovascular risk: a meta-analysis Efficacy of statins for primary prevention in people at low cardiovascular risk: a meta-analysis Tonelli M, Lloyd A, Clement F, Conly J, Husereau D, Hemmelgarn B, Klarenbach S, McAlister FA, Wiebe N, Manns B, Alberta Kidney Disease Network CRD summary The review concluded that both low- and high-potency (...) statins were efficacious in preventing death and cardiovascular-related morbidity in people at low risk of cardiovascular events, although the number needed to treat to prevent one adverse outcome was relatively high for any statin. The authors' conclusions reflect the evidence available and appear likely to be reliable. Authors' objectives To assess the efficacy and harms of statins in people at low cardiovascular risk. Searching MEDLINE and EMBASE were searched to January 2011 without language

DARE.2012

192. Statin use in postmenopausal women is associated with an increased risk of incident diabetes mellitus

Statin use in postmenopausal women is associated with an increased risk of incident diabetes mellitus Statin use in postmenopausal women is associated with an increased risk of incident diabetes mellitus | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search (...) for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Statin use in postmenopausal women is associated with an increased risk of incident diabetes mellitus Article Text Aetiology Statin use in postmenopausal women is associated with an increased risk of incident diabetes mellitus Sarah H Wild 1 , Christopher D Byrne 2 , 3 Statistics from Altmetric.com

Evidence-Based Medicine (Requires free registration)2012

193. Statin therapy and the risk of intracerebral hemorrhage: a meta-analysis of 31 randomized controlled trials

Statin therapy and the risk of intracerebral hemorrhage: a meta-analysis of 31 randomized controlled trials Statin therapy and the risk of intracerebral hemorrhage: a meta-analysis of 31 randomized controlled trials Statin therapy and the risk of intracerebral hemorrhage: a meta-analysis of 31 randomized controlled trials McKinney JS, Kostis WJ CRD summary The authors concluded that statins were not associated with increased risk of intracerebral haemorrhage and were associated with reduced (...) risk of all stroke and all-cause mortality. This was a generally well-conducted review. There was some inconsistency in direction of effects in individual studies but the authors conclusions are likely to be reliable. Authors' objectives To examine the risk of intracerebral haemorrhage due to statin use. Searching MEDLINE, Web of Science and The Cochrane Library were searched to January 2012 for publications in English; search terms were reported. Reference lists of included articles and meta

DARE.2012

194. Systematic review and meta-analysis: High-dose statin before percutaneous coronary intervention lowers risk of periprocedural myocardial infarction and 30-day major cardiac adverse events

Systematic review and meta-analysis: High-dose statin before percutaneous coronary intervention lowers risk of periprocedural myocardial infarction and 30-day major cardiac adverse events High-dose statin before percutaneous coronary intervention lowers risk of periprocedural myocardial infarction and 30-day major cardiac adverse events | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username (...) and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here High-dose statin before percutaneous coronary intervention lowers risk of periprocedural myocardial infarction and 30-day major cardiac adverse events Article Text

Evidence-Based Medicine (Requires free registration)2012

195. Primary prevention of major cardiovascular and cerebrovascular events with statins in diabetic patients: a meta-analysis

Primary prevention of major cardiovascular and cerebrovascular events with statins in diabetic patients: a meta-analysis Primary prevention of major cardiovascular and cerebrovascular events with statins in diabetic patients: a meta-analysis Primary prevention of major cardiovascular and cerebrovascular events with statins in diabetic patients: a meta-analysis de Vries FM, Denig P, Pouwels KB, Postma MJ, Hak E CRD summary This review concluded that statins reduced the incidence of a first major (...) cardiovascular or cerebrovascular event, fatal or non-fatal stroke, and fatal or non-fatal myocardial infarction, but not deaths, for patients with diabetes. The authors' conclusions reflect the evidence presented, but the very limited reporting of possible trial biases, makes it difficult to evaluate their reliability. Authors' objectives To assess the efficacy of statins for the primary prevention of a first major cardiovascular or cerebrovascular event, in patients with diabetes. Searching EMBASE, PubMed

DARE.2012

196. Is statin use associated with reduced mortality after pneumonia? A systematic review and meta-analysis

Is statin use associated with reduced mortality after pneumonia? A systematic review and meta-analysis Is statin use associated with reduced mortality after pneumonia? A systematic review and meta-analysis Is statin use associated with reduced mortality after pneumonia? A systematic review and meta-analysis Chopra V, Rogers MA, Buist M, Govindan S, Lindenauer PK, Saint S, Flanders SA CRD summary The authors concluded that current statin use was related to decreased mortality following pneumonia (...) . This effect weakened among important subgroups and studies with methodological rigour and required further study via a large randomised controlled trial. This was a well-conducted review. The authors' conclusion appears reliable and justified. Authors' objectives To evaluate the effects of statins on mortality following pneumonia. Searching Five databases – including MEDLINE, EMBASE and Cochrane Central Register of Controlled Trials (CENTRAL) – were searched to January 2012. There were no language, date

DARE.2012

197. The role of statin therapy in the prevention of atrial fibrillation: a meta-analysis of randomized controlled trials

The role of statin therapy in the prevention of atrial fibrillation: a meta-analysis of randomized controlled trials The role of statin therapy in the prevention of atrial fibrillation: a meta-analysis of randomized controlled trials The role of statin therapy in the prevention of atrial fibrillation: a meta-analysis of randomized controlled trials Fang WT, Li HJ, Zhang H, Jiang S CRD summary This review concluded that statins significantly decreased the risk of atrial fibrillation (...) , with the benefit seemingly more pronounced in secondary rather than primary prevention. Lack of reporting of the review process, the potential for missed trials, substantial variation between the included trials and their methodological limitations, mean the reliability and applicability of the results and overall conclusions are uncertain. Authors' objectives To investigate whether statins could reduce the risk of atrial fibrillation. Searching PubChem Compound, MEDLINE, EMBASE, Cochrane Central Register

DARE.2012

198. Is statin-associated cognitive impairment clinically relevant? A narrative review and clinical recommendations

Is statin-associated cognitive impairment clinically relevant? A narrative review and clinical recommendations Is statin-associated cognitive impairment clinically relevant? A narrative review and clinical recommendations Is statin-associated cognitive impairment clinically relevant? A narrative review and clinical recommendations Rojas-Fernandez CH, Cameron JC CRD summary This review concluded that there was insufficient evidence to make any confident conclusions about whether statins can (...) cause or contribute to clinically meaningful cognitive impairment. Despite the uncertainty of data quality, the authors' conclusions reflect the evidence presented and seem reliable. Authors' objectives To explore potential adverse effects of statins on cognition and consider the established vascular and putative cognitive benefits against the risk of adverse effects. Searching MEDLINE, EMBASE and The Cochrane Library were searched from inception to November 2011 for studies published in any

DARE.2012

199. Systematic review and meta-analysis: Intensive statin therapy, compared with moderate dose, increases risk of new onset diabetes but decreases risk of cardiovascular events

Systematic review and meta-analysis: Intensive statin therapy, compared with moderate dose, increases risk of new onset diabetes but decreases risk of cardiovascular events Intensive statin therapy, compared with moderate dose, increases risk of new onset diabetes but decreases risk of cardiovascular events | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts (...) OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Intensive statin therapy, compared with moderate dose, increases risk of new onset diabetes but decreases risk of cardiovascular events Article Text Therapeutics Systematic review and meta-analysis

Evidence-Based Medicine (Requires free registration)2012

200. Depression 3 and 9 months after discharge is less common in cardiac patients who are receiving statins at discharge

Depression 3 and 9 months after discharge is less common in cardiac patients who are receiving statins at discharge Depression 3 and 9 months after discharge is less common in cardiac patients who are receiving statins at discharge | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name (...) or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Depression 3 and 9 months after discharge is less common in cardiac patients who are receiving statins at discharge Article Text Prognosis Depression 3 and 9 months after discharge is less common in cardiac patients who are receiving statins at discharge Statistics from

Evidence-Based Mental Health2012